Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

IAS Conference Begins, Report Says Economic Crisis Forcing Africans Living With HIV/AIDS Off Life-Saving Medications
At a news conference opening the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention on Sunday in Cape Town, South Africa, Julio Montaner, president of the International AIDS Society, expressed disappointment that the "G8 ignored the HIV-AIDS issue at its annual summit this month," which was "just four years after pledging at the 2005 Gleneagles [G8] summit to fight for universal access to AIDS treatment by 2010," the Globe and Mail reports. "The silence of the G8 leaders is not just pathetic, it is criminal," Montaner said. The Global and Mail writes, "Cutting back on HIV-AIDS treatment programs during the recession will mean billions or even trillions of dollars in additional costs over the long term, especially because of growing scientific evidence that anti-retroviral medicine for AIDS patients can be crucial in preventing the transmission of the AIDS virus, Dr. Montaner said" (York, 7/20).
generic viagra online
Obama Defends Reform To Seniors Worried About Medicare Cuts
On Tuesday, President Obama pitched Democrats" health reform plans to senior citizens and assured them that Medicare benefits would not be cut to pay for covering the uninsured, the New York Times reports. Meanwhile, members of Congress said they were "deluged" with constituent calls expressing concern over the future of their Medicare coverage.
News of the day
Groundbreaking DKT/TOTAL Ethiopia Initiative To Promote Condoms To Housemaids Launched
DKT Ethiopia and TOTAL Ethiopia have formed a groundbreaking partnership to run a pilot project to promote condoms to housemaids and other low-income women.
Diagnostics

Stem Cell Therapeutics Receives Clearance From Health Canada To Proceed With The Phase IIb Clinical Stroke Trial

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)("SCT" or "the Company") has received a No Objection Letter ("NOL") from Health Canada for the modified REGENESIS protocol using NTx®-265 for a Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are pleased that Health Canada has issued an NOL for the modified REGENESIS clinical trial. This welcome development means that we are able to proceed with recruitment of patients, testing the NTx®-265 regimen in patients with acute ischemic stroke in Canada again and demonstrating the ability of this novel approach to speed recovery from stroke disabilities. This satisfying development can be directly attributed to the perseverance and strong belief of all the SCT staff that NTx®-265 will, in the future, redefine the therapies available to patients recovering from acute ischemic stroke, traumatic brain injury, and neurological disease." About REGENESIS (a Phase II prospective, randomized, double-blind, placebo controlled study of NTx®-265: hCG and epoetin alfa in acute ischemic stroke patients): NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. SCT received clearance from the FDA to proceed with the Phase IIb stroke trial on May 15, 2009. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009